The emergence of PD-1/PD-L1 and CTLA-4 inhibitors have transformed the overall paradigm of cancer treatment. Further enhancement in genomic fingerprinting and continuous efforts by researchers have further led to identification of lymphocyte activation gene-3 as a potential immunotherapeutic target.
LAG3 Inhibitor Emerging As New Era For Targeted Therapy Approach Says Kuick Research
Global LAG 3 Inhibitors Trials Intelligence Report Highlights:
- Global LAG 3 Inhibitors Market Dynamics
- Clinical Approaches to Target LAG 3 Inhibitors
- Role of LAG 3 Inhibitors in Cancer, Autoimmune Disorders
- Number of LAG 3 Inhibitors Drug In Trials
- LAG 3 Inhibitors Approved Patent Insight
- LAG 3 Inhibitors Trials By Phase, Company, Country, Indication
- Company Agreement/Partnership/Deals For Ongoing Trials
- Global LAG 3 Inhibitor Market Future Outlook
For Report Sample Contact neeraj@kuickresearch.com
The emergence of PD-1/PD-L1 and CTLA-4 inhibitors have transformed the overall paradigm of cancer treatment. Further enhancement in genomic fingerprinting and continuous efforts by researchers have further led to identification of lymphocyte activation gene-3 (LAG-3) as a potential immunotherapeutic target. It was first identified as a receptor expressed on activated CD4+ and CD8+ T-cells and natural killer cells. However, further studies have revealed its over-expression on several cancers including melanoma, non-small cell lung cancer, colorectal cancer, non-Hodgkin lymphoma, and others; thus making it idea target for the drug development process.
Several pharmaceutical companies have developed a robust pipeline of LAG-3 inhibitors in their pipeline indicated for the management of several cancers. Current clinical trials are mainly evaluating the role of LAG-3 inhibitors in monotherapy as well as in combination with PD-1/PD-L1 inhibitor, CTLA-4 inhibitors, vaccines or other emerging immune checkpoint inhibitors. The combinational therapy is expected to dominate the market owing to its enhanced efficiency, synergistic effects, and ability to overcome drug resistance in cancer patients. For instance, recent preliminary data from the trial suggested enhanced anti-tumor response of combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 in gastric cancer patients.
The pipeline for novel LAG-3 inhibitors is highly crowded and consists of several potential drugs including Relatlimab, Sym022, TSR-033, BI 754111, and FS118; which are mainly present in initial stages of clinical trials. However, Relatlimab developed by Bristol Myers Squibb represents one of the most advanced stage LAG-3 inhibitor which is present in phase-III clinical trial. Recently in September 2021, US FDA has accepted for priority review the Biologics License Application (BLA) for the LAG-3-blocking antibody relatlimab and nivolumab fixed-dose combination, administered as a single infusion, for the treatment of adult and pediatric patients (12 years and older and weighing at least 40 kg) with unresectable or metastatic melanoma. The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 19, 2022, suggesting that the drug will enter the market by 2022.
Currently, the market for LAG-3 inhibitor is mainly domination by therapeutic monoclonal antibodies which is mainly due to their large number of ongoing clinical trials and robust pipeline. Several monoclonal antibodies targeting LAG-3 have entered the market including MK-4280, Relatlimab, REGN3767, TSR-033, and others. As LAG-3 inhibitors are mainly efficient in combinational approaches, researchers have also developed several bispecific antibodies which have the ability to bind two epiotpes simultaneously. The bispecific antibodies show enhanced efficacy, reduced administration, and also reduces the overall cost of therapy. As of now, only a few bispecific antibodies have entered clinical trials which are present at early stages. However, their conferred advantages over monoclonal antibodies will drive further research and development in this domain during forthcoming years.
Apart from cancer, researchers are also evaluating the role of novel immune checkpoint in other therapeutic conditions including HIV and autoimmune disorders such as psoriasis, diabetes, ulcerative colitis, and others. As of now, these studies are mainly confined to in-vivo and preclinical studies and are expected to be translated to clinical stages in forthcoming years, thus propelling the growth of market. The global LAG-3 inhibitor market is anticipated to grow with high growth rates in coming years which is mainly attributed to increase in prevalence of cancer, unmet need of targeted drugs, and large number of ongoing clinical trials. . Furthermore, about 15 clinical trials are ongoing in US, which will boost the regional market. Keeping in mind, the high adoption rates, presence of large pharmaceutical giants, and rising geriatric population; it is expected that US will remain at front foot in the global LAG-3 inhibitor market during the forecast period.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366